Native Americans At Disadvantage as DEA Settles Opioid Case Among Pharma Execs
Washington, D.C. – Senate health committee Chair Bernie Sanders (I-Vt.) is set to scrutinize the executives of three major pharmaceutical companies today on the issue of prescription drug prices. The focus on healthcare policy has already begun in anticipation of a potential Republican return to the White House in 2025. One of the influential figures in this conversation is Brian Blase, former member of the Trump administration and current president of the Paragon Health Institute, …